[1] |
Cheng J, Wang L, Zhang H, et al. Diagnostic value of symptom screening for pulmonary tuberculosis in China. PLoS One, 2015,10(5):e0127725. doi: 10.1371/journal.pone.0127725.
|
[2] |
姜世闻. 采取综合措施提高肺结核患者病原学检出率. 中国防痨杂志, 2019,41(5):477-479. doi: 10.3969/j.issn.1000-6621.2019.05.001.
|
[3] |
全国第五次结核病流行病学抽样调查技术指导组, 全国第五次结核病流行病学抽样调查办公室. 2010年全国第五次结核病流行病学抽样调查报告. 中国防痨杂志, 2012,34(8):485-508.
|
[4] |
World Health Organization. Global tuberculosis report 2020. Gevena: World Health Organization, 2020.
|
[5] |
Cheng S, Chen W, Yang Y, et al. Effect of diagnostic and treatment delay on the risk of tuberculosis transmission in Shenzhen, China: an observational cohort study, 1993—2010. PLoS One, 2013,8(6):e67516. doi: 10.1371/journal.pone.0067516.
|
[6] |
Martinez L, Xu L, Chen C, et al. Delays and pathways to final tuberculosis diagnosis in patients from a referral hospital in urban China. Am J Trop Med Hyg, 2017,96(5):1060-1065. doi: 10.4269/ajtmh.16-0358.
|
[7] |
中华人民共和国国家卫生和计划生育委员会. WS 288—2017 肺结核诊断. 2017-11-09.
|
[8] |
Sharma SK, Kohli M, Yadav RN, et al. Evaluating the diagnostic accuracy of Xpert MTB/RIF assay in pulmonary tuberculosis. PLoS One, 2015,10(10):e0141011. doi: 10.1371/journal.pone.0141011.
|
[9] |
Policy Statement: Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF System. Geneva: World Health Organization, 2011.
|
[10] |
李静, 桂晓红, 孙丕, 等. MGIT液体培养基检测分枝杆菌效果的评价. 中华检验医学杂志, 2011,34(2):111-114. doi: 10.3760/cma.j.issn.1009-9158.2011.02.004.
|
[11] |
朱丽娜, 雷永良, 俞凯狄, 等. 液体快速培养在结核分枝杆菌分离培养中的应用. 中国卫生检验杂志, 2015,25(13):2112-2114.
|
[12] |
温贵华, 刘晋洪, 刘婷, 等. 结核分枝杆菌快速培养基临床应用研究. 国际检验医学杂志, 2012,33(5):526-527. doi: 10.3969/j.issn.1673-4130.2012.05.007.
|
[13] |
李亮, 刘宇红, 马艳, 等. 我国结核病防治服务体系的演变和思考. 中国防痨杂志, 2016,38(11):904-907. doi: 10.3969/j.issn.1000-6621.2016.11.002.
|
[14] |
王辰, 刘春涛. 为结核病历史性地回归呼吸病学而奋斗. 中国呼吸与危重监护杂志, 2016,15(1):1. doi: 10.7507/1671-6205.2016001.
|
[15] |
CRyPTIC Consortium and the 100,000 Genomes Project,Allix-Béguec C, Arandjelovic I, et al. Prediction of susceptibility to first-line tuberculosis drugs by DNA sequencing. N Engl J Med, 2018,379(15):1403-1415. doi: 10.1056/NEJMoa1800474.
|